How can patient care be improved beyond medical treatment?

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 337-344

  Pagnoux, Christian ^a   Guillevin, Loïc ^a  

^a Université Paris 5 ^*  (France)

Author keywords

Prophylaxis against opportunistic infections; Systemic necrotizing vasculitides; Treatment

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CALCIUM; CD20 ANTIBODY; COLECALCIFEROL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETHAMBUTOL; FOLIC ACID; GONADORELIN; HEMOPOIETIC GROWTH FACTOR; ISONIAZID; IVERMECTIN; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; ORAL CONTRACEPTIVE AGENT; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB; TESTOSTERONE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VALACICLOVIR;

AMENORRHEA; ANEMIA; ARTICLE; AZOOSPERMIA; BACTERIAL INFECTION; BLADDER CANCER; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CYTOPENIA; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FEMALE INFERTILITY; GONAD DYSFUNCTION; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LIVER TOXICITY; LUNG TOXICITY; LUNG TUBERCULOSIS; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; LYMPHOMA; MILIARY TUBERCULOSIS; MYCOSIS; NECROTIZING ARTERITIS; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OVARY INSUFFICIENCY; PARASITOSIS; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN CANCER; STRONGYLOIDIASIS; SUBGLOTTIC STENOSIS; SURVIVAL RATE; TUBERCULOUS LYMPHADENITIS; VIRUS INFECTION; VITAMIN SUPPLEMENTATION;

EID: 17644361898     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.11.005     Document Type: Review

References (48)

1. L. Gayraud P. Guillevin et al. followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients Arthritis Rheum 44 2001 666-675zz
2. E. Jayne K. Rasmussen et al. randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 2003 36-44
3. L. Guillevin P. Cohen A. Mahr et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients Arthritis Rheum 49 2003 93-100
4. A. Guillevin P. Mahr et al. corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa Arthritis Rheum 51 2004 482-487
5. J.W. Tervaert M.G. Huitema R.J. Hene et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre Lancet 336 1990 709-711
6. B.A. Cruz J. Ramanoelina A. Mahr et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit Rheumatology (Oxford) 42 2003 1183-1188
7. L. Gayraud P. Guillevin et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides Br J Rheumatol 36 1997 1290-1297
8. D. Adu A. Pall R.A. Luqmani et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis QJM 90 1997 401-409
9. L. Guillevin F. Lhote P. Cohen et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients Medicine (Baltimore) 74 1995 238-253
10. G.P. Finn B. Sidau & I.C. Shaw Protecting the bladder from cyclophosphamide with mesna N Engl J Med 314 1986 61 (letter)
11. M.B. Haselberger & T.L. Schwinghammer Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy Ann Pharmacother 29 1995 918-921
12. C. Talar-Williams Y.M. Hijazi M.M. Walther et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 1996 477-484
13. E. Zonzits W. Aberer & G. Tappeiner Drug eruptions from mesna after cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis Arch Dermatol 128 1992 80-82
14. L. Mouthon P. le Toumelin M.H. André et al. Polyarteritis nodosa and Churg-Strauss angiitis: Characteristics and outcome in 38 patients over 65 years Medicine (Baltimore) 81 2002 27-40
15. B. Godeau V. Coutant-Perronne D. Lê Thi Huong et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases J Rheumatol 21 1994 246-251
16. C. Jarrousse C. Carles-Bonnet H. Niel et al. Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in the conscious rat Am J Physiol 264 1993 G816-G823
17. R.M. Jasmer P. Nahid & P.C. Hopewell Clinical practice. Latent tuberculosis infection N Engl J Med 347 2002 1860-1866
18. R.M. Jasmer D.C. Snyder J.J. Saukkonen et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial Clin Infect Dis 38 2004 363-369
19. W.J. Blumberg R.E. Burman et al. Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis Am J Respir Crit Care Med 167 2003 603-662
20. P.B. Keiser & T.B. Nutman Strongyloides stercoralis in the immunocompromised population Clin Microbiol Rev 17 2004 208-217
21. R. Portugal R. Schaffel L. Almeida N. Spector & M. Nucci Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: A randomized double-blind placebo-controlled study Haematologica 87 2002 663-664
22. F.C. Kuipers Fatal superinfection with Strongyloides stercoralis in a patient treated with immunosuppressive agents Ned Tijdschr Geneeskd 128 1984 2449-2451
23. P. Bartolucci J. Ramanoelina P. Cohen et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients Rheumatology (Oxford) 41 2002 1126-1132
24. P. Lamprecht J. Voswinkel T. Lilienthal et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis Rheumatology (Oxford) 41 2002 1303-1307
25. O. Gause E. Arbach et al. of remission with infliximab in active generalized Wegener's granulomatosis is effective but complicated by severe infections Arthritis Rheum 48 2003 S208
26. A.D. Booth P.A. Bacon M.E. Griffith et al. Infliximab in ANCA-associated vasculitis: The ACTIVE trial Kidney Blood Press Res 26 2003 292
27. J. Cohen A.J. Pinching A.J. Rees & D.K. Peters Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease QJM 51 1982 1-15
28. C.G. Kallenberg C.A. Stegeman & J.W. Tervaert Staphylococcus aureus, trimethoprim - sulfamethoxazole, and Wegener's granulomatosis Sarcoidosis Vasc Diffuse Lung Dis 13 1996 253-255
29. G.S. Leavitt & A.S. Hoffman The role of trimethoprim/ sulfamethoxazole in the treatment of Wegener's granulomatosis Arthritis Rheum 31 1988 1073-1074
30. K. de Groot E. Reinhold-Keller E. Tatsis et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/ sulfamethoxazole Arthritis Rheum 39 1996 2052-2061
31. E. Reinhold-Keller K. de Groot H. Rudert et al. Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease QJM 89 1996 15-23
32. C.A. Langford M.C. Sneller C.W. Hallahan et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis Arthritis Rheum 39 1996 1754-1760
33. P.A. Hill Gastrointestinal small vessel vasculitis in a patient with crescentic glomerulonephritis and longstanding idiopathic neutropenia treated with G-CSF Pathology 35 2003 179-183
34. M.V. Andavolu & L.J. Logan Leukocytoclastic vasculitis as a complication of granulocyte colony-stimulating factor (G-CSF) - a case study Ann Hematol 78 1999 79-81
35. Y.D. Farhey & J.H. Herman Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty's syndrome J Rheumatol 22 1995 1179-1182
36. C.A. Langford J.H. Klippel J.E. Balow et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: Rheumatologic and renal diseases Ann Intern Med 128 1998 1021-1028
37. C.A. Langford J.H. Klippel J.E. Balow et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity Ann Intern Med 129 1998 49-58
38. E.M. McDermott & R.J. Powell Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide Ann Rheum Dis 55 1996 224-229
39. D. Lê Thi Huong Z. Amoura P. Duhaut et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide J Rheumatol 29 2002 2571-2576
40. R. Abir B. Fisch A. Raz et al. Preservation of fertility in women undergoing chemotherapy: Current approach and future prospects J Assist Reprod Genet 15 1998 469-477
41. A. Masala R. Faedda S. Alagna et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia Ann Intern Med 126 1997 292-295
42. C. Talar-Williams Y.M. Hijazi M.M. Walther et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 1996 477-484
43. C.D. Radis L.E. Kahl G.L. Baker et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study Arthritis Rheum 38 1995 1120-1127
44. E.G. Seidman & D.E. Furst Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine J Rheumatol 29 2002 2484-2487
45. C.A. Marra J.M. Esdaile & A.H. Anis Practical pharmacogenetics: The cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine J Rheumatol 29 2002 2507-2512
46. T. Girard A. Mahr L.H. Noël et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study Rheumatology (Oxford) 40 2001 147-151
47. C.A. Stegeman Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis Nephrol Dial Transplant 17 2002 2077-2080
48. J.W. Tervaert C.A. Stegeman & C.G. Kallenberg Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides Sarcoidosis Vasc Diffuse Lung Dis 13 1996 241-245